Publications - Corcept Therapeutics

PUBLICATIONS

Scientific journal publications or scientific congress presentations may include information regarding investigational products or uses.

A mixed glucocorticoid/mineralocorticoid selective modulator with dominant antagonism in the male rat brain.

Atucha et al. • 2015 • Endocrinology. 2015;156(11):4105-4114.

Selective Glucocorticoid Receptor Modulators (SGRMs) delay castrate-resistant prostate cancer growth.

Kach et al. • 2017 • Mol Cancer Ther. 2017;16(8):1680-1692.

The biology of hormone refractory prostate cancer. Why does it develop?

Isaacs JT • 1999 • Urol Clin North Am. 1999;26(2):263-73.

“Targeting” triple-negative breast cancer: the lessons learned from BRCA1-associated breast cancers.

Nanda R. • 2011 • Semin Oncol. 2011;38(2):254-62.

Minireview: nuclear receptors and breast cancer.

Conzen SD • 2008 • Mol Endocrinol.2008;22(10):2215-28.

Glucocorticoid receptor activation inhibits chemotherapy-induced cell death in high-grade serous ovarian carcinoma.

Stringer-Reasor et al. • 2015 • Gynecol Oncol. 2015;138(3):656-62.

Glucocorticoid receptor activity contributes to resistance to androgen-targeted therapy in prostate cancer.

Isikbay et al. • 2014 • Horm Cancer. 2014;5(2):72-89.

Glucocorticoid receptor antagonism as a novel therapy for triple-negative breast cancer.

Skor et al. • 2013 • Clin Cancer Res. 2013;19(22):6163-72.

Steroid receptors aplenty in prostate cancer.

Sharifi N. • 2014 • N Engl J Med. 2014;370(10):970-1.

Glucocorticoid receptor expression in 20 solid tumor types using immunohistochemistry assay.

Block et al. • 2017 • Cancer Manag Res. 2017;9:65-72.